Product logins

Find logins to all Clarivate products below.


Aortic Repair Devices | Market Insights | Japan | 2023

Despite the negative—albeit relatively limited—impact of the ongoing COVID-19 pandemic, the Japanese aortic repair device market will grow at a modest rate, which in turn is attributed to shift towards premium-priced endovascular procedures, large and expanding patient pool, and launch of new aortic repair devices in Japan during the forecast period. However, the growth will be limited to some extent by unavailability of certain aortic stent graft brands and pricing pressure due to changes in reimbursement.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for aortic repair devices in Japan from 2019 through 2031.

Related Medtech Insights Reports

Report
Sports Medicine Devices – Market Insights – Japan
Technological investments, adoption of premium-priced products, increased market awareness through educational programs, improved surgeon training, and high levels of sports participation will…
Report
Aortic Repair Devices – Market Insights – United States
The US aortic repair device market will grow moderately during upcoming years, driven by the uptake of innovative stent grafts and the positive clinical evidence that supports their adoption. The…
Report
Large-Joint Reconstructive Implants – Market Insights – Japan
Growth in large-joint reconstructive procedure volumes is being driven by favorable demographic trends and increased demand for innovative technologies. However, market expansion is partly…
Report
Trauma Devices – Market Insights – Japan
The Japanese trauma device market will experience marginal growth through 2034, primarily fueled by the adoption of innovative, premium-priced technologies. This upward trend is further supported…
Report
Cardiac Rhythm Management Devices – Market Insights – Japan
The Japanese CRM device market will grow over the forecast period. The introduction of novel products—such as the Aurora EV-ICD and dual-chamber leadless pacemakers—and favorable reimbursement…